Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-06-20 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It references specific listing rules from the Stock Exchange of Hong Kong (SEHK) and details repurchases of shares, including dates, quantities, and prices. The document includes confirmations by the company secretary regarding compliance with listing rules and legal requirements. The content is focused on reporting share repurchase transactions and changes in issued share capital, which aligns with announcements about share buybacks or capital changes rather than a full financial report or earnings release. The document is about reporting transactions in the company's own shares (share repurchases) and related confirmations. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS). The document length (over 10,000 characters) and detailed transactional data support this classification with high confidence.
2023-06-20 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It references compliance with the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong. The content details repurchases of shares, dates, prices, and confirmations by the company secretary. This is a regulatory disclosure about share repurchases and capital changes, not a full financial report or earnings release. It fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2023-06-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It includes detailed information about repurchase of shares, dates, prices, and confirmations related to compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase activity and changes in issued shares, which aligns with announcements about share repurchases or capital changes. The document is not a full financial report, earnings release, or management discussion, but a regulatory disclosure about share capital changes and buybacks. Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS). The document length and detail support a high confidence in this classification.
2023-06-15 English
SUPPLEMENTAL ANNOUNCEMENT ON PROVISION FOR IMPAIRMENT OF ASSETS FOR 2022&#x3b; BUSINESS UPDATES&#x3b; AND CHANGE IN USE OF PROCEEDS
Capital/Financing Update Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding a supplemental announcement on provision for impairment of assets for 2022, business updates, and change in use of proceeds. It references the 2022 Annual Results Announcement and the 2022 Annual Report but does not contain the full annual report itself. The document includes detailed business updates, R&D pipeline status, and changes in use of proceeds, which are typical of a capital/financing update or business operational update. It is not a full annual report (10-K), nor is it a simple announcement of a report publication (RPA). The document is lengthy (15,000 characters) and contains substantive information about financial provisions, business strategy, and capital allocation. The focus on change in use of proceeds and business updates aligns best with Capital/Financing Update (CAP).
2023-06-14 English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to non-registered shareholders of Ascletis Pharma Inc. It informs them about the availability of the company's current corporate communications, including the Notice of Annual General Meeting (AGM), on the company's and HKExnews websites. It also includes a request form for shareholders to opt to receive printed versions of these communications. The document does not contain any financial statements, detailed reports, or substantive financial data. It is essentially an announcement and facilitation for shareholders to access or request corporate communications, specifically mentioning the Notice of AGM. Given the content and length (6574 characters), it is not the AGM materials themselves but a communication about them and how to obtain them. Therefore, it fits best as a Report Publication Announcement (RPA), which covers announcements regarding the timing, release, or availability of company reports or communications.
2023-06-05 English
Form of Proxy for the 2023 Annual General Meeting
AGM Information Classification · 95% confidence The document is a Form of Proxy for the 2023 Annual General Meeting (AGM) of Ascletis Pharma Inc. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including receiving and considering the audited financial statements and reports, re-election of directors, appointment of auditors, and granting mandates related to shares. The content is focused on the proxy voting process for the AGM rather than the AGM materials or the full annual report itself. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy forms.
2023-06-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.